Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
By C. Blanke, G. Demetri, M. von Mehren, M. Heinrich, B. Eisenberg, J. Fletcher, Christopher Corless, C. Fletcher, P. Roberts, Daniela Heinz and 3 more. Journal of Clinical Oncology, 2008
988 citations recorded by the source corpus.
Subfields: Gastroenterology, Pulmonary and Respiratory Medicine, Rheumatology
View Paper: https://www.semanticscholar.org/paper/83750349a44c93611108200f381f665c73094bad
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Gastroenterology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Risk stratification of patients diagnosed with gastrointestinal stromal tumor. (2008, background): “Imatinib is now being explored as adjuvant therapy in patients with primary resectable GIST because clinical trials in patients with unresectable or metastatic GISTs found that imatinib substantially improves survival in advanced GIST and is generally well tolerated [7,8].”
- One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. (2012, background): “Primary tumor diameter, median (range), cm 9 (2-35) 10 (2-40)”